(Q36531285)

14 August 2017

1 reference

title

The role of imaging in the surveillance of urologic malignancies (English)

1 reference

14 August 2017

Timothy J Bradford

1

1 reference

PubMed ID

16829272

14 August 2017

James E Montie

series ordinal

2

1 reference

PubMed ID

16829272

14 August 2017

Khaled S Hafez

series ordinal

3

1 reference

14 August 2017

1 August 2006

1 reference

Urologic Clinics of North America

14 August 2017

1 reference

14 August 2017

33

1 reference

14 August 2017

3

1 reference

14 August 2017

377-396

1 reference

14 August 2017

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

The changing face of low-risk prostate cancer: trends in clinical presentation and primary management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

ACTIVE SURVEILLANCE WITH SELECTIVE DELAYED INTERVENTION: USING NATURAL HISTORY TO GUIDE TREATMENT IN GOOD RISK PROSTATE CANCER

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Watchful waiting in prostate cancer: review and policy proposals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

The role of serial transrectal ultrasonography in a 'watchful waiting' protocol for men with localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Follow-up of conservatively managed prostate cancer: watchful waiting and primary hormonal therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Radical prostatectomy versus watchful waiting in early prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Levels of prostate specific antigen that predict skeletal spread in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Are serial bone scans useful for the follow-up of clinically localized, low to intermediate grade prostate cancer managed with watchful observation alone?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

EAU guidelines on prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Natural history of progression after PSA elevation following radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Prostate cancer: radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

PROSTASCINT scan for staging prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Surveillance of patients with prostate cancer after treatment: the roles of serologic and imaging studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Follow-up surveillance strategies for genitourinary malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Imaging for recurrent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Detection of vertebral metastases: comparison between MR imaging and bone scintigraphy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Magnetic resonance imaging for detection of prostate cancer metastatic to bone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

PET in the management of urologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Positron emission tomography with 18fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Is Useless for the Detection of Local Recurrence after Radical Prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Positron emission tomography in urologic oncology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Recurrent prostate cancer following external beam radiotherapy: follow-up strategies and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

The positive yield of imaging studies in the evaluation of men with newly diagnosed prostate cancer: a population based analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Brachytherapy for prostate cancer: follow-up and management of treatment failures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Prostate cancer: cryotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Treatment of Advanced Renal Cell Carcinoma—Traditional Methods and Innovative Approaches

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Diagnosis and management of renal cell carcinomaA clinical and pathologic study of 309 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Renal cell carcinoma: evaluation of the 1997 TNM system and recommendations for follow-up after surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Patterns of tumor recurrence and guidelines for followup after nephron sparing surgery for sporadic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Pulmonary resection of metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Results of surgical treatment of renal cell carcinoma with solitary metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Salvage surgery for renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Renal cell carcinoma metastatic to the lung: potential benefit in the combination of biological therapy and surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Increased incidence of serendipitously discovered renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Renal imaging for diagnosis and staging of renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Management of renal masses in patients medically unsuitable for nephrectomy--natural history, complications, and outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Conservative management of incidental contrast-enhancing renal masses as safe alternative to invasive therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Renal cryoablation: outcome at 3 years.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Clinical experience with open renal cryoablation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

The radiographic evolution of radio frequency ablated renal tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Long-term followup of patients with renal cell carcinoma treated with radio frequency ablation with curative intent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Value of routine radionuclide bone scans in renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Association of radionuclide bone scan and serum alkaline phosphatase in patients with metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Positron emission tomography for urological tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

International patterns and trends in testis cancer incidence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Second malignancies following pure seminoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Second malignancies following radiotherapy for testicular seminoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Risk of Second Malignant Neoplasms Among Long-term Survivors of Testicular Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Surveillance in stage I testicular cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Surveillance for stage I testicular germ cell tumours: results and cost benefit analysis of management options.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Stage I seminoma of the testis: is post-orchidectomy surveillance a safe alternative to routine postoperative radiotherapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Surveillance following orchidectomy for stage I seminoma of the testis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

EAU guidelines on testicular cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Efficacy of routine follow-up after first-line treatment for testicular cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Routine computerised tomographic scans of the thorax in surveillance of stage I testicular non-seminomatous germ-cell cancer--a necessary risk?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Radiotherapy for testicular seminoma stage I: treatment results and long-term post-irradiation morbidity in 365 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Stage I testicular seminoma: results of adjuvant irradiation and surveillance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

The role of positron emission tomography in germ cell cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Use of fluorodeoxyglucose positron emission tomography scans in patients with advanced germ cell tumour following chemotherapy: single-centre experience with long-term follow up.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

[Positron emission tomography with [18 F]-2-fluoro-2-deoxy-D-glucose (18FDG-PET) in diagnosis of retroperitoneal lymph node metastases of testicular tumors]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors--prospects for management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

A novel surveillance protocol for stage I nonseminomatous germ cell testicular tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Comparison of surveillance and retroperitoneal lymph node dissection in Stage I nonseminomatous germ cell tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

PROGRESSION DETECTION OF STAGE I NONSEMINOMATOUS TESTIS CANCER ON SURVEILLANCE: IMPLICATIONS FOR THE FOLLOWUP PROTOCOL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumours: 17 years' experience in a national study in New Zealand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Follow-up of clinical stage I testicular cancer patients: cost and risk benefit considerations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Active surveillance after orchiectomy for nonseminomatous testicular germ cell tumors: late relapse may occur

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

A surveillance study of clinical stage I nonseminomatous germ cell tumors of the testis: 10-year followup

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Late recurrence in 1263 men with testicular germ cell tumors. Multivariate analysis of risk factors and implications for management.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Risk Factors for Relapse in Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors: Results of the German Testicular Cancer Study Group Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Management of recurrence and follow-up strategies for patients with nonseminoma testis cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Routine chest X-rays have no additional value in the detection of relapse during routine follow-up of patients treated with chemotherapy for disseminated non-seminomatous testicular cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Metastatic nonseminomatous germ cell tumors of the testis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcino

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Is biopsy of the contralateral testis necessary in patients with germ cell tumors?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

The long-term outcome in patients with superficial transitional cell carcinoma of the bladder: a single-institutional experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Guidelines on bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Should the followup of patients with bladder cancer include routine excretory urography?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Upper tract surveillance in primary bladder cancer follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Intravenous urography in urinary tract surveillance in carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Upper urinary tract tumors developing after treatment of superficial bladder cancer: 7-year follow-up of 591 consecutive patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Upper tract transitional cell carcinoma following treatment of superficial bladder cancer with BCG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Upper tract tumors in patients with primary bladder cancer followed for 15 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Upper-tract tumors after an initial diagnosis of bladder cancer: argument for long-term surveillance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Routine excretory urography in follow-up of superficial transitional cell carcinoma of bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Local recurrence after cystectomy alone for bladder carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Contemporary cystectomy versus preoperative radiation plus cystectomy for bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Prognostic factors, pattern of recurrence and survival in a Danish bladder cancer cohort treated with radical cystectomy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Stage specific follow-up strategy after cystectomy for carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Local recurrence and survival following nerve sparing radical cystoprostatectomy for bladder cancer: 10-year followup

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

A stage specific approach to tumor surveillance after radical cystectomy for transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Urinary diversion-related outcome in patients with pelvic recurrence after radical cystectomy for bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Local recurrence after cystectomy and survival of patients with bladder cancer: a population based study in greater amsterdam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Pelvic recurrence after radical cystectomy without preoperative radiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Follow-up strategies and management of recurrence in urologic oncology bladder cancer: invasive bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Upper tract recurrences following radical cystectomy: an analysis of prognostic factors, recurrence pattern and stage at presentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Upper tract tumours following cystectomy for bladder cancer. Is routine intravenous urography worthwhile?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

The risk of upper tract recurrence following cystectomy in patients with transitional cell carcinoma involving the distal ureter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Development of upper tract carcinoma after cystectomy for bladder carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Urothelial tumors of upper tract following treatment of primary bladder transitional cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Upper tract transitional cell carcinoma following cystectomy for bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Urinary tract abnormalities: initial experience with multi-detector row CT urography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

CT urography of urinary diversions with enhanced CT digital radiography: preliminary experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Patients at high risk for upper tract urothelial cancer: evaluation of hydronephrosis using high resolution magnetic resonance urography.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Nonnephrotoxic, dynamic, contrast enhanced magnetic resonance urography: use in nephrology and urology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Use of magnetic resonance urography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Gadolinium-enhanced excretory MR urography after low-dose diuretic injection: comparison with conventional excretory urography.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

MR urography: examination techniques and clinical applications.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Patient radiation dose at CT urography and conventional urography.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-D-glucose.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Visualisation of bladder cancer using (11)C-choline PET: first clinical experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Surveillance and management of recurrence for upper tract transitional cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Transitional cell carcinoma of the renal pelvis or ureter: patterns of failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Conservative Management of Upper Urinary Tract Tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Is nephroureterectomy necessary in all cases of upper tract transitional cell carcinoma? Long-term results of conservative endourologic management of upper tract transitional cell carcinoma in individuals with a normal contralateral kidney

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Primary percutaneous approach to upper urinary tract transitional cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

EAU guidelines on diagnosis and treatment of upper urinary tract transitional cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Current practice patterns in urologic management of upper-tract transitional-cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Risk factors for the development of bladder cancer after upper tract urothelial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Natural history, management, and surveillance of recurrent squamous cell penile carcinoma: a risk-based approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

EAU Guidelines on Penile Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

Nephron sparing surgery for renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

inferred from DOI database lookup

7 January 2021

based on heuristic

Stage I nonseminomatous germ-cell testicular cancer--management options and risk-benefit considerations.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

inferred from DOI database lookup

7 January 2021

based on heuristic

The value of the biopsy of the contralateral testis in patients with testicular germ cell cancer: the recent German experience.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2006.03.001

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.UCL.2006.03.001

1 reference

14 August 2017

1 reference

PubMed ID

16829272